QOL MEDICAL

QOL Medical to Acquire Evoke Pharma for $11 Per Share, Securing GIMOTI Nasal Spray for Diabetic Gastroparesis

- QOL Medical will acquire specialty pharmaceutical company Evoke Pharma for $11.00 per share in cash, representing a 139.7% premium to the most recent closing price. - The acquisition centers on GIMOTI, the first and only FDA-approved nasal spray formulation of metoclopramide for treating acute and recurrent diabetic gastroparesis in adults. - The transaction, unanimously approved by both boards of directors, is expected to close by the end of 2025 through a tender offer structure. - QOL Medical's deep experience in gastrointestinal disorders commercialization positions the company to expand GIMOTI's reach among patients and healthcare providers.